The Less is More Study
Novel Extensions of Alcohol Contingency Management in People Living With HIV
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Emmely Pavila
- Phone Number: 352-273-9562
- Email: empavila17@ufl.edu
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- Recruiting
- University of Miami
-
Contact:
- Varan Govind, PhD
- Phone Number: 305-243-8096
- Email: vgovind@med.miami.edu
-
Gainesville, Florida, United States, 32610
- Recruiting
- University of Florida
-
Contact:
- Emmely Pavila, B.A., B.S.
- Phone Number: 352-273-9562
- Email: empavila17@ufl.edu
-
Principal Investigator:
- Yan Wang, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Frequent alcohol use in the past 30 days based on responses on the Timeline Followback (TLFB; Sobell and Sobell, 2003)
- HIV positive
- Fluency in English
- Willingness to attempt alcohol abstinence for at least 30 days and then to attempt alcohol use on fewer days than at baseline after that
- Willingness to use smartphone applications and biosensor devices (i.e., breathalyzer device and wrist sensor) for alcohol use reduction purposes in the study. If participants do not have a compatible smartphone to use, they will be loaned one by the study
Exclusion Criteria:
- Psychiatric conditions that would interfere with participation in the study
- Current alcohol withdrawal as indicated by a score of 8 or higher on the Clinical Institute Withdrawal Scale (CIWA; Sullivan et al., 1989) or lifetime history of medically assisted detoxification
- Two positive breath alcohol concentration (BrAC) readings (i.e., > 0.00%) at an in-person screening appointment. After participants blow their first positive BrAC, they will be allowed to reschedule and participate at another time, however if they blow a second positive BrAC, they will be excluded from this study and offered referrals for alcohol treatment.
- Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors
- Psychosis or other severe psychiatric disability
- Pregnancy, nursing or lack of reliable birth control use for women who have not yet reached menopause
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Non-Contingent Condition
Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, encouragement to reduce drinking but payment not based on drinking.
|
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
|
|
Experimental: mHealth and CM
Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings.
Participants will also interact with a mobile health application to facilitate drinking reduction.
|
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
Participants will engage with an application designed to gamify drinking reduction.
|
|
Experimental: CM
Participants will wear a wrist biosensor with daily CM based on smartphone breathalyzer readings for 30 days; then for a second 30 days, weekly CM based on wrist biosensor readings
|
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning
Brief counseling including personalized feedback on breath alcohol concentration, cognitive task performance and physical functioning.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent days abstinent via smartphone breathalyzer readings
Time Frame: Baseline to 30 Days
|
Within-subject comparison between percent abstinent days based on smartphone breathalyzer readings during the 30-Day Phase 1 Contingency Management induction compared to the 30-day baseline period based on self-report on the timeline followback
|
Baseline to 30 Days
|
|
Predict percent days abstinent via smartphone breathalyzer readings based on risk factors.
Time Frame: Baseline to 30 Days
|
All participants will attempt to reduce alcohol consumption.
Only those who are able to will continue to the second phase of the intervention.
We will seek to identify which factors are predictive of abstinence.
|
Baseline to 30 Days
|
|
Perceived value and ease of use of novel contingency management strategies to reduce alcohol consumption.
Time Frame: 30 Days to 60 Days
|
Participants will engage in a Contingency Management program aimed at reducing alcohol consumption.
A novel CM delivery system will be used intended to gamify the process.
|
30 Days to 60 Days
|
|
Drinking reduction through Contingency Management will predict non-drinking outcomes
Time Frame: Baseline to 90 days
|
Participants who are able to successfully reduce their alcohol consumption may see other health benefits including reduced HIV viral load.
|
Baseline to 90 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent days abstinent via wrist biosensor readings
Time Frame: Baseline to 60 Days
|
Among responders during the Phase 1 Contingency Management induction period, comparison among Phase 2 study conditions regarding percent abstinent days based on wrist biosensor readings.
Percent days abstinent at baseline based on self-report and based on smartphone breathalyzer readings during Phase 1 will be included in this model.
|
Baseline to 60 Days
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percent days abstinent via self-report
Time Frame: Baseline to 180 Days
|
Among responders during the Phase 1 Contingency Management induction period, comparison among Phase 2 study conditions regarding percent abstinent days during the post-intervention, follow-up period based on self-report assessed with the timeline followback from days 61-180.
Percent days abstinent at baseline based on self-report and based on smartphone breathalyzer readings during Phase 1 and based on wrist biosensor readings during Phase 2 will be included in this model.
|
Baseline to 180 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Robert Leeman, Ph.D, University of Florida
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CED000000577 (Other Identifier: UF IRB Number)
- P01AA029543 (U.S. NIH Grant/Contract)
- PRO00035889 (Other Identifier: UFIRST)
- OCR41499 (Other Identifier: UF OnCore)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.